ArticleCell division2009
Proteomics, pathway array and signaling network-based medicine in cancer.
Article in Cell division, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 69 citations in OpenAlex.
- Protein profiling of preeclampsia placental tissues.PloS one · 2014Trial
- Peptide Arrays as Tools for Unraveling Tumor Microenvironments and Drug Discovery in Oncology.Cells · 2026Review
- A review on in-silico analysis of immune cell trafficking and interactions with the tumour microenvironment.Frontiers in oncology · 2026Review
- Analytical Techniques as Indicators of Biomarkers in Proteomics Cancer Diagnosis.Anti-cancer agents in medicinal chemistry · 2026Review
- High-throughput proteomics: a methodological mini-review.Laboratory investigation; a journal of technical methods and pathology · 2022Review
- Alterations of Signaling Pathways in Essential Thrombocythemia with Calreticulin Mutation.Cancer management and research · 2021Article
- A Novel Method to Identify Autoantibodies against Putative Target Proteins in Serum from beta-Thalassemia Major: A Pilot Study.Biomedicines · 2020Article
- Topological properties and in vitro identification of essential nodes of the Paclitaxel and Vincristine interactomes in PC-3 cells.Biomedical journal · 2019Article
- Signaling pathway network alterations in human ovarian cancers identified with quantitative mitochondrial proteomics.The EPMA journal · 2019Article
- A benchmark for comparing precision medicine methods in thyroid cancer diagnosis using tissue microarrays.Bioinformatics (Oxford, England) · 2018Article
- Article
- Novel potential serological prostate cancer biomarkers using CT100+ cancer antigen microarray platform in a multi-cultural South African cohort.Oncotarget · 2016Article
- Biological Networks for Cancer Candidate Biomarkers Discovery.Cancer informatics · 2016Review
- Proteomics: A new perspective for cancer.Advanced biomedical research · 2016Review
- Protein Profiling of Bladder Urothelial Cell Carcinoma.PloS one · 2016Article
- Article
- Immune-Signatures for Lung Cancer Diagnostics: Evaluation of Protein Microarray Data Normalization Strategies.Microarrays (Basel, Switzerland) · 2015Article
- Pathway and network approaches for identification of cancer signature markers from omics data.Journal of Cancer · 2015Review
- Pathway-based analysis of breast cancer.American journal of translational research · 2014Article
- Elevated cell proliferation and VEGF production by high-glucose conditions in Müller cells involve XIAP.Eye (London, England) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a multifaceted disease that results from dysregulated normal cellular signaling networks caused by genetic, genomic and epigenetic alterations at cell or tissue levels. Uncovering the underlying protein signaling network changes, including cell cycle gene networks in cancer, aids in understanding the molecular mechanism of carcinogenesis and identifies the characteristic signaling network signatures unique for different cancers and specific cancer subtypes. The identified signatures can be used for cancer diagnosis, prognosis, and personalized treatment. During the past several decades, the available technology to study signaling networks has significantly evolved to include such platforms as genomic microarray (expression array, SNP array, CGH array, etc.) and proteomic analysis, which globally assesses genetic, epigenetic, and proteomic alterations in cancer. In this review, we compared Pathway Array analysis with other proteomic approaches in analyzing protein network involved in cancer and its utility serving as cancer biomarkers in diagnosis, prognosis and therapeutic target identification. With the advent of bioinformatics, constructing high complexity signaling networks is possible. As the use of signaling network-based cancer diagnosis, prognosis and treatment is anticipated in the near future, medical and scientific communities should be prepared to apply these techniques to further enhance personalized medicine.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.